Howard Horn
Executive VP of Corporate Strategy & CFO at Ultragenyx Pharmaceutical
Total operating expenses for the quarter were $282,000,000 which included R and D expenses of $166,000,000 SG and A expenses of $88,000,000 and cost of sales of 29,000,000 Operating expenses included non cash stock based compensation of $40,000,000 For the quarter, net loss was $151,000,000 or $1.57 per share. As of March 31, we had $563,000,000 in cash, cash equivalents and marketable securities, which reflects $45,000,000 in cash payments made for two milestones during the first quarter of twenty twenty five that were achieved in the fourth quarter of twenty twenty four. Specifically, 30,000,000 for a GTX-one hundred two Phase three study milestone and $15,000,000 for an EVKYSA sales milestone. In the first quarter of twenty twenty five net cash used in operations was $166,000,000 Recall in the first quarter of the year we typically use more operating cash than in the subsequent three quarters because it includes items like the payment of annual bonuses. In addition, first quarter net cash used in operations also included the $30,000,000 GTX-one hundred two development milestone payment I mentioned earlier.